formative data in these three studies come from the obligate heterozygotes, the mothers. The relative risk estimates of breast cancer for these mothers were 3.37, 3.32, and 7.1, respectively, based on comparisons with population mortality or incidence rates. With the index-test method, we had estimated the relative risk of breast cancer for A-T heterozygotes to be 3.8 (6) . Our recently reported comparison of the mortality of carrier and noncarrier grandparents in A-T families (11) , which is based on comprehensive data collection and genotyping, is consistent with these findings. The relative risk of death from all cancers for male and female carriers was 2.6.
A relative risk of breast cancer greater than 3 is compatible with three recent studies (12) (13) (14) , which found the proportion of A-T mutation carriers to be 8%-10% in populations of breast cancer patients. Two of these studies (12, 13) employed exonby-exon screening, and one (14) used the protein truncation test. Earlier studies that had yielded lower estimates of the heterozygote frequency in narrowly selected populations had detected only truncating mutations (15, 16) or had dismissed missense mutations as neutral polymorphisms (17) .
These data may be compared with those of "control" population samples. In two studies in the United States (12, 15) , approximately 1% of the population has been found to be A-T mutation carriers. Even though only a single truncating A-T mutation was sought in a sample from the general Dutch population, it was found in 0.7% of this sample (14) . Estimates (10, 18 ) of the population frequency of A-T heterozygotes based on the Hardy-Weinberg principle are inevitably too low because this calculation depends on accurate measurement of the birth incidence of the homozygotes, which is not currently feasible. The important point is that prevalence surveys (10,18) typically underestimate the birth incidence of genetic syndromes severalfold.
Therefore, reliable estimates of the frequency of A-T heterozygotes in the general population and in groups of breast cancer patients will require highly sensitive, specific, and cost-effective methods of mutation screening. Mutation detection at the A-T locus is challenging because the gene has 66 exons that span 150 kb of genomic DNA. Exon-by-exon screening methods have detected mutations in 57%-85% of the specific chromosomes 11 that must be mutated because they were found in patients with A-T (19, 20) . It is likely that many of the "missing" mutations are due to sequence changes deep within introns that lead to splicing errors that produce an altered gene product. On the positive side, hundreds of different mutations-truncating, missense, splicing, and in-frame insertions or deletions-have already been found in the DNA of A-T patients or their parents. In all reported studies of A-T patients, truncating mutations constituted more than 50% of all identified mutations.
Remarkably, missense mutations at the A-T locus were found at a high frequency in three series of breast cancer patients from the general population (11, 12, 21) and at a relatively high frequency in one set of population control subjects (21) but not in two others (11, 12) . Truncating mutations predominated in breast cancer patients in another population study (14) . In my unpublished data from A-T families, the proportion of missense and truncating mutations in relatives with breast cancer is not substantially different from the proportion of each type in the entire sample.
It is important to recognize that some missense mutations may not produce clinically recognizable A-T in homozygotes or compound heterozygotes but may increase the risk of breast cancer in heterozygotes. Stankovic et al. (22) reported that patients homozygous for the 7271T→G missense mutation had extremely mild neurologic symptoms, leading to the diagnosis of A-T only in adult life. Breast cancer was present in two female homozygotes in this family and in a total of three relatives in this and another family with this mutation. The finding that A-T patients who are compound heterozygotes for a missense mutation are taller and live longer (20) is further support for the concept that such mutations lead to a mild A-T phenotype.
At this time, all statistical estimates demonstrating an elevated risk of breast cancer for A-T heterozygotes derive from studies that included diverse mutations. To estimate disease risks for specific mutations or groups of mutations, appropriate samples and research designs must be selected.
In summary, individuals heterozygous for a mutation at the A-T locus, who constitute at least 1% of the general population, have a risk of developing female breast cancer that is more than threefold greater than that of noncarriers. Hypotheses about predisposition to other cancers remain to be tested through genotyping of cancer cases within families of A-T homozygous probands. Clinical testing to determine who carries an A-T mutation and measurements of heterozygote frequency in groups of cancer patients and the general population will become increasingly practical and reliable as methods of mutation detection and evaluation improve.
